Abstract
The RAAS is an important pharmacologic target as the system is involved in cardiovascular (CV) and renovascular disease. Ang II is the key component of RAAS. The intervention to the RAAS can be achieved in different stages. While angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two big groups that target the RAAS, aliskiren a direct renin inhibitor that became clinically feasible in 2007 with the launch of aliskiren. In this review, we will discuss direct renin inhibition as a new concept for pharmacotherapy of hypertension and aliskiren, the first oral direct renin inhibitor, as a new class of antihypertensive drug based on new evidence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
